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Background: Obstructive sleep apnea-hypopnea (OSAH) is a risk factor for development of
systemic arterial hypertension (SAH) and can worse the control of established SAH. We inves-
tigated the effects of long-term continuous positive airway pressure (CPAP) treatment in
controlling and preventing SAH in a large cohort of subjects referred for sleep study for sus-
pected OSAH.
Methods: In 495 subjects of whom 422 with OSAH and 73 without OSAH, the clinical history was
obtained, arterial blood pressure was measured and the current anti-hypertensive drugs was
recorded at diagnosis and/or at CPAP start. Subjects were interviewed after a follow-up period
of (mean  SD) 3.4  2.2 yr (range 1e8 yr) and divided in patients with moderate-to-severe
OSAH (nZ 125) who referred to use CPAP regularly for at least 4 h every night (group 1), with
moderate-to-severe OSAH (n Z 70) who refused or abandoned the CPAP treatment after few
weeks (group 2), with mild OSAH (n Z 227) with no CPAP indication (group 3) and simple
snorers or normals (n Z 73) (group 4). For each group clinical status, BMI, and changes in
SAH therapy and occurrence of SAH were assessed at the follow-up.
Results: At the follow-up, a higher risk of increasing treatment for SAH was found for group 2
and group 3 versus group 1 (ORZ 5, 95%CI 1e20, p < 0.01 and ORZ 3, 95%CI 1e10, p < 0.05),
respectively. The occurrence of SAH was lower (p < 0.001) in the group 1 (1.9%), vs group 2
(35.9%), 3 (21.1%) and 4 (18.6%).03996821; fax: þ39 0303996138.
dalicivili.brescia.it (L. Corda).
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1330 P. Bottini et al.Conclusions: In moderate-to-severe OSAH patients, long-term CPAP treatment significantly
reduces the development of SAH and, in those with SAH at baseline, the need of anti-
hypertensive drugs.
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Obstructive sleep apneaehypopnea (OSAH) is widely
recognized as an independent risk factor for the develop-
ment of systemic arterial hypertension (SAH)1e3 and today
considered as the first identifiable cause of secondary SAH.4
Several mechanisms have been invoked potentially linking
OSAH to SAH: an increased nighttime and daytime sympa-
thetic activity (due to chemoreflex stimulation by nocturnal
intermittent hypoxia),5 an impaired arterial vasodilation5
(secondary to endothelial dysfunction and systemic
inflammation)6 and a reduced inhibitory baroreflex gain
(due to an abnormal autonomic function).7 Among other
factors, the sustained arterial pressure is thought to
markedly increase the cardiovascular morbility and
mortality risk observed in OSAH patients.8
The administration of continuous positive airway pres-
sure (CPAP) during sleep is the treatment of choice for
moderate-to-severe and/or symptomatic OSAH patients.
CPAP has been shown to be able to positively modify all
the above mentioned “intermediate mechanisms”
inducing or worsening SAH in OSAH.9 The results of
previous studies looking at the effect of CPAP treatment
on the arterial blood pressure levels in OSAH patients,
however, were controversial possibly because influenced
by several factors such as the severity of OSAH,5 the
presence or absence of daytime sleepiness,5 the degree
and duration of SAH before the treatment5 including the
occurrence of resistant SAH,5 CPAP proper titration,5 the
average time of the CPAP use during the night,5 age and
gender of patients5 and finally the duration of the treat-
ment.5 In fact, the vast majority of these studies were
conducted for weeks or few months and very few studies
investigated the CPAP effects on arterial blood pressure
for a longer time.9e11
Therefore, the objective of the present study was to
assess the long-term effects of CPAP treatment on the
arterial blood pressure levels in a single-center, large
cohort of subjects referred for sleep study for suspected
OSAH. In particular, we evaluated the occurrence of SAH
and the pharmacological changes of established SAH in
patients with moderate-to-severe OSAH according to the
CPAP treatment adherence.Methods
This was a monocentric, observational, cohort study
performed in 820 subjects referred for clinically suspected
OSAH who underwent either a full polysomnography or
a cardio-respiratory monitoring at the sleep laboratory of
the medical Division of the hospital of Umbertide (Perugia,
Italy) between October 2000 and December 2007.Scoring of sleep stages and associated events was made
according to the recommendation of American Academy of
Sleep Medicine.12 At the time of the first visit, clinical
assessment including medical history, physical examina-
tion, and office measurement of systemic arterial blood
pressure was performed for each subject. Arterial blood
pressure measurements were determined by averaging two
readings of systolic and diastolic blood pressure obtained at
5-min interval using a mercury sphygmomanometer after
subjects had been seated in a chair with the dominant arm
supported at the heart level for at least 10 min.13 Normal
values were considered as lower than 130 mmHg and
85 mmHg for systolic and diastolic blood pressure, respec-
tively and SAH was defined by arterial blood pressure values
higher than 140/90 mmHg.13 In case of subjects with SAH,
the current anti-hypertensive treatment was recorded. The
subjects with apneaehypopnea index (AHI) more than 20
and those with AHI more than 5 and excessive daytime
somnolence, as scored by Epworth Sleepiness Scale (ESS) as
higher than 10, were subsequently titrated for optimal
CPAP. The baseline clinical assessment in the first visit, the
interpretation of diagnostic and titration sleep studies, and
follow-up were performed by the same physician (PB) for
all subjects. The flowchart of the study is shown in Fig. 1.
At the time of the interview performed in the years
2008e09, among 820 subjects who attended the sleep
study, 726 were successfully contacted. After two phone
calls done by physicians from a single university center,
only 495 subjects accepted to give information about the
clinical status including the present BMI, the last 3 values of
systemic arterial blood pressure measured by their family-
doctors, any changes in anti-hypertensive therapy and the
compliance with CPAP treatment. Among 422 subjects with
OSAH, 195 were recommended to adopt the CPAP treat-
ment (group 1 and 2), while 227 had no indication for CPAP
treatment (AHI < 20, group 3); 73 were simple snorers or
normals (group 4). At the follow-up 125 of 195 OSAH
patients who were advised to adopt the CPAP treatment,
used CPAP all nights for more than 4 h every night (group 1),
while 70 refused to use CPAP since the beginning or aban-
doned the CPAP treatment after few weeks of initial
treatment (group 2). Subjects without OSAH represented
the control group (group 4). The protocol was approved by
Ethic Committee of “Spedali Civili, Brescia” (no approval
number available).
Statistical analysis
Continuous variables were expressed as mean  SD, and
categorical variables were expressed as a percentage. The
primary outcomes were the pathological increase of
systolic and diastolic arterial blood pressure (yes or not) in
previously normotensive subjects as well as variations of
Figure 1 Flow-chart of the study with identification of each group.
Effect of CPAP on hypertension in OSAH 1331anti-hypertensive treatment (more or equal-less pills/drug)
in the subjects with SAH among different groups during the
follow-up. We analyzed the different risk of such outcomes
among various groups as odd ratios. Baseline characteristics
of patients were compared by two-tailed unpaired t-test
for continuous variables and two-tailed Fisher exact test or
Chi square for nominal variables. Analysis of variance of
changes of variables of interest among groups was per-
formed after checking the normality of the data set; ifFigure 2 Changes of the anti-hypertensive treatment at the
end of the follow-up in subjects with established SAH at
baseline in each group. Better (white columns) means reduc-
tion of anti-hypertensive drugs or pills; stable (grey columns)
means no change in anti-hypertensive therapy; worse (black
columns) means increase in anti-hypertensive drugs or pills.significant variance was observed, multiple comparisons
were performed using unpaired Student’s t-test, corrected
by the Bonferroni method.
P < 0.05 was considered as significant. Statistical soft-
ware (SPSS version 12.0.1, Chicago, IL.) was used for data
processing and statistical analysis.Results
The baseline clinical features of all the subjects are shown
in Table 1 and those of each group in Table 2. The mean of
the follow-up period was 3.4  2.2 yr (range 1e8 yr) and
was similar among the groups. Age, gender, and BMI were
not different between group 1 and 2. AHI was greater in the
group 1 than in the group 2, although subjects in both
groups suffered from moderate-to-severe OSAH. BMI and
AHI was significantly lower in groups 3 and 4 than in groups
1 and 2. Age in the group 4 was lesser than in group 2.
The prevalence of SAH at baseline is shown in Table 2.
The amounts of anti-hypertensive drugs assumed by the
subjects with established SAH at baseline were shown
according to the different groups in Table 3.
In subjects with normal values of systemic arterial
pressure (<130/85 mmHg) at the beginning of the study,
the SAH incidence was 1.9% in the group 1, 35.9% in group 2
and 21.1% and 18.6% in groups 3 and 4 (Fig. 3). At the
beginning the sleepiness, assessed according to the ESS,
was significantly greater in the group 1 than group 2 and 3
(see Table 2).
Table 1 Baseline characteristics of population studied.
Subjects n Z 495
Age, yr 58.5  12.9
Male 407 (82.2%)
Female 88 (17.7%)
BMI (kg/m2) 30.1  5.3
Prevalence of systemic hypertension 40.4% (200/495)
Data are expressed as mean  SD or n (%).
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groups 3 and 4 versus group 1 (OR Z 27, 95%CI 3e216,
p < 0.0001, ORZ 14, 95%CI 2e105, p < 0.001 and ORZ 12,
95%CI 1e96, p < 0.01), respectively.
During the follow-up among subjects with SAH 5% of the
subjects in the group 1 increased their anti-hypertensive
therapy, using more pills or more drugs, while 26% of the
subjects in the group 2 needed to do it. Also 15% of subjects
in the group 3 and 14% in the group 4 increased their anti-
hypertensive therapy. A higher risk of increasing treatment
for SAH was found for group 2 and group 3 versus group 1
(OR Z 5, 95%CI 1e20, p < 0.01 and OR Z 3, 95%CI 1e10,
p < 0.05), respectively (Fig. 2).
At the follow-up BMI was 32.2  5.3 for group 1,
31.1  5.1 for group 2, 27.8  4.1 for group 3, and
26.5  3.3 for group 4, respectively. The changes between
baseline and follow-up BMI were not significantly different
among different groups.
Among patients of the group 1 who had established SAH,
a significantly higher probability of reducing the number of
anti-hypertensive pills and/or drugs at the follow-up
(OR Z 5.3, 95%IC 1.8e15.8, p < 0.002) was observed in
those who were taking a greater amount of anti-hyperten-
sive drugs (more than two versus two or less) at the
beginning of CPAP treatment. In contrast, this was not
observed for BMI, AHI and somnolence score.
At the follow-up the all-cause mortality was equal to
0.8% (1 subject) in the group 1, 5.7% (4 subjects) in the
group 2 and 0.9% (2 subjects) in the group 3.Table 2 Baseline anthropometric characteristics and apnea-hy
Group 1 Group 2
OSAH with CPAP (AHI> 20) OSAH without
Number 125 (25.2%) 70 (14.1%)
Age, yr 59.8  11.1 62.2  12.2
Male 111 (88.8%) 62 (88.5%)
Female 14 (11.2%) 8 (11.4%)
BMI (kg/m2) 33.2  11.1 32.7  5.5
AHI 52.8  18.7 45.3  22.2*
ESS 10.3  3.9 8.6  4.6x
Prevalence of SAH 57.6% (72/125 pts) 41.2% (29/70
Data are expressed as mean  SD or n (%).
xp < 0.05 vs Group 1.
*p < 0.01 vs Group 1; #p < 0.01 vs Group 2; p < 0.01 vs Group 3.
**p < 0.001 vs Group 1; ##p < 0.001 vs Group 2; p < 0.001 vs Grou
ESS Z Epworth Sleepiness Score; SAH Z Systemic arterial hypertensiDiscussion
The main finding of this study is that long-term treatment
with CPAP is associated with a significant, protective
effect towards SAH development and SAH worsening in
subjects with moderate-to-severe OSAH versus both
untreated moderate-to-severe OSAH and mild OSAH.
Although this is an observational study and arterial blood
pressure was not recorded as mean of 24-h ambulatory
monitoring, its results are important due to the longest
follow-up ever reported and the large number of subjects
involved, all coming from a single center, so avoiding
inter-operator variability in diagnosis of OSAH, titration
of CPAP, therapeutic advices and initial control of the
device use.
The effect on arterial blood pressure of CPAP treatment
in OSAH, although repeatedly assessed in several small
studies, has not been convincingly demonstrated due to
the variable results. A recent meta-analysis performed on
12 randomized trials with a duration ranged from 1 to 12
weeks, including 572 OSAH patients, found only a small
reduction on arterial blood pressure (in average less than
2 mmHg in mean 24-h arterial blood pressure) in those
treated with CPAP.14 Interestingly, some sub-populations of
hypertensive OSAH patients seemed to benefit more from
CPAP treatment such as those with more severe OSAH
(according to AHI and/or number of arousals per hour of
sleep), longer duration and gravity of SAH, greater
somnolence and obviously better adherence to the treat-
ment. Although it would have seemed reasonable to
recommend CPAP treatment to OSAH patients with severe
SAH (mainly in those with other cardiovascular risk factors)
also with the goal of lowering SAH, nevertheless the results
of the trials were too modest, possibly because of the short
duration and the small number of subjects in each study, to
justify the CPAP use in other groups of hypertensive OSAH
patients only to obtain a better control of SAH. For
instance, in a very recently published multi-centre
randomized trial, involving 340 OASH patients with
untreated SAH, where the effects on arterial blood pres-
sure, assessed by a 24-h ambulatory monitoring, werepopnea index (AHI) of each group.
Group 3 Group 4
CPAP (AHI> 20) Mild OSAH (AHI< 20) Controls (AHI< 5)
227 (45.8%) 73 (14.7%)
58.5  12.7 58.8  13.3x
184 (81%) 50 (68.5%)
43 (18.9%) 23 (31.5%)
28.6  4.4** 27.1  3.9**
10.9  10.4** 2.3  1.3** 
7.2  2.8 ## /
pts) 37.4% (85/227 pts) 19.2% (14/73 pts)
p 3.
on; pts Z patients.
Table 3 Amount of therapy of SAH at baseline in hyper-
tensive subjects.
Number of
patients
Group 1
(72)
Group 2
(29)
Group 3
(85)
Group 4
(14)
Number of anti-hypertensive drugs
1 28 (38.9%) 13 (44.8%) 35 (41.1%) 7 (50%)
2 24 (33.3%) 12 (41.4%) 37 (43.5%) 4 (28.6%)
3 18 (25%) 3 (10.3%) 11 (12.9%) 3 (21.4%)
4 1 (1.4%) 0 (0%) 2 (2.3%) 0 (0%)
5 1 (1.4%) 1 (3.4%) 0 (0%) 0 (0%)
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versus that assigned to sham treatment, the significant
reduction of SAH in the subjects receiving CPAP was rela-
tively small, less than 3 mmHg drop in mean 24-h ambu-
latory blood pressure, still questioning the clinical
relevance of these results.15 In addition, recently it has
been published16 a paper with the observation that 3
months of CPAP therapy similarly lowers blood pressure in
patients with OSAH with metabolic syndrome or some of its
component.
Mayer and coll. treating with CPAP 12 hypertensive
OSAH patients found that daytime SAH decreased signifi-
cantly only after 6 months, while nighttime SAH was
acutely reduced.17 More recently, in a sample of 98
hypertensive OSAH patients Dernaika et al. investigated
the effect of the one year CPAP treatment on arterial
blood pressure and reported a significant better control of
blood pressure only in those with resistant SAH.11 Again, in
contrast with the findings of Robinson et al.,18 Barbe` et al.
showed that in a large sample of 359 hypertensive OSAH
patients without hypersomnolence, those treated for at
least one year with CPAP can exhibit a significant SAH
reduction if the adherence was adequate (more than 5 h
per night).9 In fact, in the present study after a mean
follow-up of 3.4 yr, patients with moderate-to-severe
OSAH and established SAH who declared an adequate
adherence to CPAP (group 1), showed a worsening in the
SAH control significantly lesser than that reported in the
hypertensive OSAH patients of other groups (groups 2 andFigure 3 Absence (white columns) or presence (black
columns) of established SAH at the end of the follow up in
subjects with normal arterial blood pressure at baseline in
each group.3). Therefore, the duration of CPAP treatment seems very
important to judge carefully its effects on arterial blood
pressure in OSAH patients. This is in keeping with the
notion that it may take more than several months of CPAP
treatment to obtain a reduction of sympathetic activity in
OSAH patients.19
In our study, very impressive was the prevention of the
SAH development in normotensive moderate-to-severe
OSAH patients treated with CPAP as compared to the
untreated ones. This finding is in agreement with the
results obtained by Campos et al.20 and in a small
randomized trial performed in 36 severe OSAH patients with
similar arterial blood pressure values and percentage of
pre-hypertension and masked hypertension, according to
both office and 24-h monitoring measurement, who were
assigned to a sham or CPAP treatment for only 3 months.21
While no changes in arterial blood pressure were observed
in the control group, the OSAH patients in the treated group
showed a significant reduction of the frequency of pre-
hypertension and masked hypertension, reflecting
a protective effect of the active treatment.
Mild OSAH patients had a lower risk to develop SAH as
compared to untreated moderate-to-severe OSAH
patients, although they showed a frequency of new SAH
similar to control subjects. It is somehow surprising that
either group 3 (mild-to-moderate OSAH patients) or group
4 (controls) showed a higher frequency of new SAH than
group 1 (moderate-to-severe OSAH patients treated with
CPAP). Actually, CPAP does deeply influence and possibly
may delay the effects of several pathogenic mechanisms
leading to increase systemic vascular resistance and this
cannot be usually offered to mild-to-moderate OSAH
patients. Moreover, in this group and mainly in the
group 4 less attention could be paid to favorable changes
in life style such as physical activity, diet and medical
checkups.
The present study has some clear limitations. Physical
activity and dietary habits were not checked in our
population and these could be confounding factors.
However, it is highly improbable that in a long run greater
physical activity and low salt and less caloric diet only
pertain to the moderate-to-severe OSAH patients treated
with CPAP as compared with others groups. The contrary
would be more plausible considering the less favorable
long-term results on arterial blood pressure in the
untreated OSAH patients. On the other hand, the average
decrease in BMI was similar in the different groups of
OSAH patients, arguing against these potential
confounders.
We have not objective measurements of the CPAP use
throughout such a prolonged period of treatment. Even if
the CPAP use would have been lower than one reported by
group I patients, the effects we recorded on control and
prevention of SAH would be even more impressive in the
absence of other obvious explanations.
In conclusion, the long-term CPAP treatment is highly
effective in moderate-to-severe OSAH patients to decrease
the SAH occurrence in those who were normotensive and to
improve the SAH control in those who were hypertensive
before its implementation as compared with both
untreated moderate-to-severe OSAH patients and mild-to-
moderate OSAH patients.
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